Journal issues > Issue Special, April 2025 > Highlight 2: Lymphoma in 2025

Highlight 2: Lymphoma in 2025

During the 2025 BHS General Annual Meeting (GAM), the highlights session on lymphoma provided key insights into evolving management strategies for diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Dr. Catherine Thieblemont (Hôpital Saint-Louis Paris, France) presented an in-depth overview of the latest approaches in DLBCL treatment. Consequently, Dr. Vibeke Vergote (UZ Leuven, Belgium) shared her perspective on the contemporary management of MCL, incorporating recent clinical trial data and emerging therapeutic options. Their discussions underscored the rapid advancements in lymphoma treatment and the shifting paradigms that are shaping patient care in 2025.

To read the full artice you have the following options:

Click here to log in. Register for a free subscription*

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top